Neuren Pharmaceuticals Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Neuren Pharmaceuticals Limited - overview
Established
2000
Location
-, -, Australia
Primary Industry
Biotechnology
About
Neuren Pharmaceuticals Limited specializes in developing innovative therapeutics for neurodevelopmental disabilities, focusing on improving cognitive and developmental outcomes through targeted treatment solutions. Founded in 2000 and headquartered in Melbourne, Australia, Neuren Pharmaceuticals Limited develops therapies for neurodevelopmental disorders. The company has undergone strategic pivots, including its focus on NNZ-2591, designed to address conditions like Pitt-Hopkins syndrome. In February 2005, Neuren completed an IPO, and since then, it has engaged in 3 significant deals, culminating in a PIPE funding round in which it raised USD 21.
50 mn, bringing the total amount raised to USD 21. 50 mn. Neuren Pharmaceuticals Limited focuses on the development of innovative therapeutics targeting neurodevelopmental disabilities. Their core products include NNZ-2591, designed to treat conditions such as Pitt-Hopkins syndrome by modulating neuroinflammation and promoting synaptic function.
Neuren is actively involved in clinical trials to establish the efficacy and safety of its products, targeting healthcare providers and institutions in pediatric neurology and developmental disorders. Their geographical markets extend beyond Australia, including key regions such as North America and Europe, addressing unmet medical needs in neurodevelopmental disorders. In the most recent year, 2023, Neuren Pharmaceuticals reported revenue of USD 154. 12 mn and EBITDA of USD 132.
55 mn. The company's revenue is generated through strategic partnerships and collaborations with pharmaceutical firms and research institutions, primarily revolving around the development and commercialization of their flagship product, NNZ-2591. Neuren Pharmaceuticals plans to leverage recent funding to enhance its product pipeline, focusing on new therapeutic developments aimed at expanding treatment options for neurodevelopmental disorders. The company intends to penetrate new markets, particularly in North America and Europe, by late 2024.
Recent funding, raised in the PIPE round, will be utilized to support clinical trials and strategic partnerships necessary for these expansions.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Specialty Pharmaceuticals
Website
www.neurenpharma.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.